In May 2013 the Discretionary Advisory Committee on Heritable Disorders in Newborns and Children (DACHDNC) voted to add Pompe disease (acid mattase deficiency, glycogen storage disease type II) Newborn Screening to the Recommended Uniform Screening Panel (RUSP). The final confirmation from the US Secretary of Health and Human Services (HHS) was announced in March 2015. Pompe disease is an inherited condition classified as a lysosomal storage disorder, with severity and age of onset differing depending on the form. The three forms of Pompe disease are classic infantile-onset, non-classic infantile-onset and late-onset.
NewSTEPs partners with state newborn screening programs, partner organizations and federal agencies to provide a central location for Pompe disease resources. If you have additional resources that you would like included, please contact NewSTEPs.
Newborn Screening Status: Map of the screening status of newborn screening disorders in the US.
Educational Resources: NewSTEPs has compiled educational resources that can be used to support screening efforts in states and regions. For educational resources, pertinent publications and archived webinars please visit the NewSTEPs resource library and filter for Pompe. The Clinical & Laboratory Standards Institute (CLSI) has a standards document regarding newborn screening blood spot screening for Pompe.
Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) Recommendations:
- The Addition of Pompe Disease to the Recommended Uniform Screening Panel (June 3, 2013)
- Secretary's Interim Response Regarding Committee's Recommendation to Add Pompe Disease (January 27, 2014)
- Secretary's Final Response Regarding the Commitee's Recommendation to Add Pompe (March 2, 2015)
- For information shared during recent ACHDNC meetings relative to Pompe, please visit the ACHDNC meeting wepage.